Novartis AG: Analyst support could favor the continuation of the trend to new highs
Reading Time: 2 minutes
Novartis has evolved into a focused innovation company that concentrates solely on patented, innovative pharmaceuticals. Following the spin-off of its generics division Sandoz and the divestment of other business areas, the corporation aims to transform scientific breakthroughs into life-changing therapies. The company's main solutions lie in key therapeutic areas such as cardiovascular diseases, immunology, neurology, and particularly oncology. Recent news underscores this focus on innovation. For example, in November, the EU approval for...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
